ESMO 2022 | DS-7300 demonstrates durable antitumor activity in advanced solid tumors

Toshihiko Doi, MD, PhD, National Cancer Center Hospital East, Chiba, Japan, shares the results of an extended follow-up of a Phase I/II (NCT04145622) investigating DS-7300, a B7-H3–directed antibody-drug conjugate (ADC) with a topoisomerase I inhibitor payload (DXd), in various cancers including small cell lung cancer (SCLC), metastatic castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC). DS-7300 continues to demonstrate evidence of durable antitumor activity in heavily pre-treated patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.